Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Depression and pain co-occur, even during adolescence. However, there is limited knowledge on the association between pain and lifetime depression, and which biopsychosocial measures are associated with this co-occurrence.
Methods: Cross-sectional analysis of the Adolescent Brain and Cognitive Development (ABCD) two-year follow-up. We explored associations between the presence and characteristics of past month pain (intensity, duration, activity limitations, and number of pain sites) and lifetime depression using logistic regression. We explored associations of brain structure, physical, behavioural, emotional, social, and cognitive measures with lifetime depression and past month pain compared to having had one or neither condition using multinomial logistic regression.
Results: A total of 5211 adolescents (mean age = 12.0 years) who had: (1) no lifetime mental ill-health and no pain (n = 3327); (2) pain only (n = 1407); (3) lifetime depressive disorder but no pain (n = 272); and (4) lifetime depressive disorder and pain (n = 205) were included. Pain presence was associated with lifetime depression (OR[95%CI]: 1.76 [1.45, 2.13], p < 0.001). Pain-related activity limitations (1.13 [1.06, 1.21], p < 0.001) and the number of pain sites (1.06 [1.02, 1.09], p < 0.001) were associated with lifetime depression. Various behavioural, emotional, social, and cognitive, but not brain structure or physical measures, were associated with lifetime depression and past month pain.
Limitations: Longitudinal analyses should validate prognostic markers for predicting co-occurring depression and pain.
Conclusions: Results support an association between the presence and characteristics of pain and lifetime depression during adolescence and could indicate the need for more integrated recognition and clinical care of youth experiencing both depression and pain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jad.2024.12.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Barriers and boosters of adolescent mental health recovery: The dual roles of positive and adverse childhood experiences.
J Affect Disord
September 2025
Department of Counseling, College of Education, Health, and Human Science, University of Nebraska Omaha, United States of America. Electronic address:
Background: Adverse Childhood Experiences (ACEs) and Positive Childhood Experiences (PCEs) play critical roles in adolescent mental health, influencing onset and recovery. Informed by the Social-Ecological Risk and Protective Factors framework, the current study examines ACEs as barriers and PCEs as facilitators in recovery from anxiety and depression. We used continuous score and categorical subgroup models to capture both linear and potential threshold effects.
View Article and Find Full Text PDFSteroid hormone-mediated epigenetic programming during puberty: uncovering links to depression.
Epigenomics
September 2025
McGill Group for Suicide Studies, Douglas Mental Health University Institute, Montreal, Canada.
DNA methylation (DNAm) is a key epigenetic modification that dynamically regulates eukaryotic development over time. DNAm has been found to influence a variety of biological processes in both normative and pathological states, such as depression. Since DNAm can serve as an interface between environmental influence and gene expression, it is a mechanism studied in the context of many pathologies, including psychiatric.
View Article and Find Full Text PDFImportance: Effective and well-tolerated pharmacotherapies for generalized anxiety disorder (GAD), which is one of the most common psychiatric disorders, are needed.
Objective: To determine the dose-response relationship of MM120 (lysergide D-tartrate) in adults with moderate to severe GAD.
Design, Settings, And Participants: This phase 2b, multicenter, randomized, double-blind, placebo-controlled study enrolled 198 adults aged 18 to 74 years with a primary GAD diagnosis who presented with moderate to severe symptoms (defined by a Hamilton Anxiety Rating Scale [HAM-A] score ≥20) and was conducted at 22 outpatient psychiatric research sites in the US from August 2022 to August 2023.